Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors

US11702472B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• The U.S.A., as represented by The Secretary, Department of Health and Human Services · US

Inventors

• Prasad S. Adusumilli · Edison, US
• Michel Sadelain · New York, US
• Dimiter S. Dimitrov · Frederick, US
• Yang Feng · Frederick, US

Key dates

• Filing date: Mar 17, 2020
• Grant date: Jul 18, 2023
• Expiry date: May 15, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.